Skip to main content
. 2023 Dec 6;10(1):e23368. doi: 10.1016/j.heliyon.2023.e23368

Table 2.

Antimicrobial susceptibility of the isolates.

Antimicrobial Class Antimicrobial Agent I
R
NS (I + R)
S
n (%) n (%) n (%) n (%)
Aminoglycosides Kanamycin 21 (11.5) 80 (43.7) 101 (55.2) 82 (44.8)
Gentamicin 0 (0) 45 (24.6) 45 (24.6) 138 (75.4)
Amikacin 11 (6.0) 21 (11.5) 32 (17.5) 151 (82.5)
Tobramycin 1 (0.5) 50 (27.3) 51 (27.9) 132 (72.1)
Netilmicin 6 (3.3) 24 (13.1) 30 (16.4) 153 (83.6)
Streptomycin 11 (6.0) 61 (33.3) 72 (39.3) 111 (60.7)
Quinolones Ciprofloxacin 42 (23.0) 66 (36.1) 108 (59.0) 75 (41.0)
Levofloxacin 35 (19.1) 42 (23.0) 77 (42.1) 106 (57.9)
Lomefloxacin 24 (13.1) 53 (29.0) 77 (42.1) 106 (57.9)
Norfloxacin 9 (4.9) 36 (19.7) 45 (24.6) 138 (75.4)
Ofloxacin 2 (1.1) 41 (22.4) 43 (23.5) 140 (76.5)
4th generation cephalosporin Cefepime 12 (6.6) 77 (42.1) 89 (48.6) 94 (51.4)
Beta-Lactam and beta-lactamase inhibitor Amoxicillin-clavulanate 59 (32.2) 73 (39.9) 132 (72.1) 51 (27.9)
Monobactam Aztreonam 20 (10.9) 57 (31.1) 77 (42.1) 106 (57.9)
3rd generations cephalosporin Cefpodoxime 5 (2.7) 98 (53.6) 103 (56.3) 80 (43.7)
Ceftazidime 32 (17.5) 51 (27.9) 83 (45.4) 100 (54.6)
Ceftriaxone 3 (1.6) 87 (47.5) 90 (49.2) 93 (50.8)
Cefotaxime 7 (3.8) 90 (49.2) 97 (53.0) 86 (47.0)

I: intermediate susceptibility. N: count. NS: non-susceptible. R: resistant. S: susceptible.